Journal of Neurology

, Volume 260, Issue 11, pp 2884–2889 | Cite as

LRRK2 G2385R variant carriers of female Parkinson’s disease are more susceptible to motor fluctuation

  • Chao Gao
  • Hao Pang
  • Xiao-Guang Luo
  • Yan Ren
  • Hong Shang
  • Zhi-Yi He
Original Communication

Abstract

The relation between the LRRK2 mutation and its effect on Parkinson’s disease (PD) has always caught a lot attention. Recent studies found that the G2385R polymorphism of LRRK2 may increase the risk of PD in Asian populations. Here we tried to clarify the relationship between the LRRK2 G2385R variant and the clinical profiles including motor complication in Chinese PD patients. We identified the LRRK2 variant in the Chinese Han population in northern China and evaluated the relationship between the G2385R variant and clinical profiles through comparison between 36 carriers and 139 non-carriers. We found that G2385R carriers scored significantly higher in motor fluctuation and dyskinesia than non-carriers. Logistic regression analysis showed that the G2385R variant was an independent risk factor for motor fluctuation in females (odds ratio = 12.538, 95 % CI 2.216–70.942, P = 0.004), and a Chi-squared test showed that the frequency of dyskinesia tended to be higher in the carrier group compared to the non-carrier group (16 vs. 4.4 %, P = 0.050, OR = 4.127, 95 % CI 1.074–15.864). These findings indicate that the variant was closely related to the occurrence of motor complication. Additionally, the G2385R variant was significantly related to the early-onset of PD in female carriers (20.0 vs. 1.5 %, odds ratio = 16.25, 95 % CI 1.557–169.618, P = 0.020). Our study found that the G2385R variant was significantly associated with motor complications and that this variant was an independent risk factor for motor fluctuation in females. These findings provide the necessary preliminary data to better understand the unique profile of PD G2385R variant carriers.

Keywords

LRRK2 G2385R variant Parkinson’s disease Motor complication Gender effects 

References

  1. 1.
    Lubbe S, Morris HR (2013) Recent advances in Parkinson’s disease genetics. J NeurolGoogle Scholar
  2. 2.
    Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR (2006) A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6:47PubMedCrossRefGoogle Scholar
  3. 3.
    Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan. Neurogenetics 7(3):133–138PubMedCrossRefGoogle Scholar
  4. 4.
    Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence. Hum Genet 120(6):857–863PubMedCrossRefGoogle Scholar
  5. 5.
    Li C, Ting Z, Qin X, Ying W, Li B, Guo Qiang L, Jian Fang M, Jing Z, Jian Qing D, Di Sheng C (2007) The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson’s disease. Mov Disord 22(16):2439–2443PubMedCrossRefGoogle Scholar
  6. 6.
    An XK, Peng R, Li T, Burgunder JM, Wu Y, Chen WJ, Zhang JH, Wang YC, Xu YM, Gou YR, Yuan GG, Zhang ZJ (2008) LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han-Chinese from mainland China. Eur J Neurol 15(3):301–305PubMedCrossRefGoogle Scholar
  7. 7.
    Zabetian CP, Yamamoto M, Lopez AN, Ujike H, Mata IF, Izumi Y, Kaji R, Maruyama H, Morino H, Oda M, Hutter CM, Edwards KL, Schellenberg GD, Tsuang DW, Yearout D, Larson EB, Kawakami H (2009) LRRK2 mutations and risk variants in Japanese patients with Parkinson’s disease. Mov Disord 24(7):1034–1041PubMedCrossRefGoogle Scholar
  8. 8.
    Choi JM, Woo MS, Ma HI, Kang SY, Sung YH, Yong SW, Chung SJ, Kim JS, Shin HW, Lyoo CH, Lee PH, Baik JS, Kim SJ, Park MY, Sohn YH, Kim JH, Kim JW, Lee MS, Lee MC, Kim DH, Kim YJ (2008) Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 9(4):263–269PubMedCrossRefGoogle Scholar
  9. 9.
    Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia. Parkinsonism Relat Disord 13(2):89–92PubMedCrossRefGoogle Scholar
  10. 10.
    Haas BR, Stewart TH, Zhang J (2012) Premotor biomarkers for Parkinson’s disease—a promising direction of research. Transl Neurodegener 1(1):11PubMedCrossRefGoogle Scholar
  11. 11.
    Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E (2009) The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 256(3):483–487PubMedCrossRefGoogle Scholar
  12. 12.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedCrossRefGoogle Scholar
  13. 13.
    Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534PubMedCrossRefGoogle Scholar
  14. 14.
    Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22(13):1901–1911PubMedCrossRefGoogle Scholar
  15. 15.
    Kim JM, Lee JY, Kim HJ, Kim JS, Shin ES, Cho JH, Park SS, Jeon BS (2010) The LRRK2 G2385R variant is a risk factor for sporadic Parkinson’s disease in the Korean population. Parkinsonism Relat Disord 16(2):85–88PubMedCrossRefGoogle Scholar
  16. 16.
    Fu X, Zheng Y, Hong H, He Y, Zhou S, Guo C, Liu Y, Xian W, Zeng J, Li J, Liu Z, Chen L, Pei Z (2013) LRRK2 G2385R and LRRK2 R1628P increase risk of Parkinson’s disease in a Han Chinese population from Southern Mainland China. Parkinsonism Relat Disord 19(3):397–398PubMedCrossRefGoogle Scholar
  17. 17.
    Haubenberger D, Bonelli S, Hotzy C, Leitner P, Lichtner P, Samal D, Katzenschlager R, Djamshidian A, Brucke T, Steffelbauer M, Bancher C, Grossmann J, Ransmayr G, Strom TM, Meitinger T, Gasser T, Auff E, Zimprich A (2007) A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson’s disease. Mov Disord 22(11):1640–1643PubMedCrossRefGoogle Scholar
  18. 18.
    Chan DK, Ng PW, Mok V, Yeung J, Fang ZM, Clarke R, Leung E, Wong L (2008) LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson’s disease compared to late-onset patients. J Neural Transm 115(9):1275–1277PubMedCrossRefGoogle Scholar
  19. 19.
    Tan EK, Zhao Y, Tan L, Lim HQ, Lee J, Yuen Y, Pavanni R, Wong MC, Fook-Chong S, Liu JJ (2007) Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. Mov Disord 22(12):1816–1818PubMedCrossRefGoogle Scholar
  20. 20.
    Cai J, Lin Y, Chen W, Lin Q, Cai B, Wang N, Zheng W (2013) Association between G2385R and R1628P polymorphism of LRRK2 gene and sporadic Parkinson’s disease in a Han-Chinese population in south-eastern China. Neurol SciGoogle Scholar
  21. 21.
    Tan EK, Peng R, Wu YR, Wu RM, Wu-Chou YH, Tan LC, An XK, Chen CM, Fook-Chong S, Lu CS (2009) LRRK2 G2385R modulates age at onset in Parkinson’s disease: a multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet 150B(7):1022–1023PubMedCrossRefGoogle Scholar
  22. 22.
    Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd (2008) Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70(3):200–209PubMedCrossRefGoogle Scholar
  23. 23.
    Saunders-Pullman R (2003) Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine 21(1):81–87PubMedCrossRefGoogle Scholar
  24. 24.
    Ascherio A, Weisskopf MG, O’Reilly EJ, McCullough ML, Calle EE, Rodriguez C, Thun MJ (2004) Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 160(10):977–984PubMedCrossRefGoogle Scholar
  25. 25.
    Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE (2003) Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease. Neurology 60(5):790–795PubMedCrossRefGoogle Scholar
  26. 26.
    Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A (2009) Reproductive factors, exogenous estrogen use, and risk of Parkinson’s disease. Mov Disord 24(9):1359–1365PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Chao Gao
    • 1
  • Hao Pang
    • 2
  • Xiao-Guang Luo
    • 1
    • 3
  • Yan Ren
    • 1
  • Hong Shang
    • 3
  • Zhi-Yi He
    • 1
  1. 1.Neurology Department of Shengjing Affiliated Hospital of China Medical UniversityShenyangPeople’s Republic of China
  2. 2.Department of Forensic SerologyChina Medical UniversityShenyangPeople’s Republic of China
  3. 3.Department of Laboratory MedicineFirst Affiliated Hospital of China Medical UniversityShenyangPeople’s Republic of China

Personalised recommendations